Tymlos Shortage: What Providers and Prescribers Need to Know in 2026

Tymlos (abaloparatide) remains one of the most effective anabolic agents available for high-risk osteoporosis patients. Its Phase 3 ACTIVE trial demonstrated an 86% reduction in new vertebral fractures and a 43% reduction in nonvertebral fractures versus placebo. Despite its clinical efficacy, many patients — and their providers — are frustrated by the barriers between the prescription pad and the patient's first injection.

This guide is written for endocrinologists, rheumatologists, PCPs, orthopedists, and other clinicians who prescribe Tymlos or are considering it for their patients. We'll cover the clinical and logistical landscape in 2026, including prior authorization strategies, specialty pharmacy routing, savings programs, and when to pivot to alternatives.

Is There a Formal Tymlos Shortage?

No. As of early 2026, Tymlos (abaloparatide) is not on the FDA or ASHP drug shortage databases. Ipsen (which acquired Radius Health in 2022) continues to manufacture and distribute abaloparatide through specialty pharmacy channels. However, access friction remains significant due to:

Mandatory specialty pharmacy distribution (not stocked at standard retail pharmacies)

Cold chain requirements (refrigerated pre-use, room temperature post-opening)

Near-universal prior authorization requirements with variable approval timelines

Step therapy requirements on many plans (requiring documented bisphosphonate failure or intolerance)

High list price (~$4,000-$4,300/month) driving payer gatekeeping

No generic abaloparatide approved (unlike teriparatide, which has generic alternatives)

Prior Authorization: Documentation That Matters

Almost all commercial and Medicare plans require prior authorization for Tymlos. Building a complete, well-documented PA request at the time of prescribing significantly increases the likelihood of first-pass approval and reduces delays.

Key elements to include in every Tymlos PA request:

DXA results with T-scores at the lumbar spine, femoral neck, and total hip

Fracture history (prior vertebral or nonvertebral fragility fractures)

Prior treatment history including drug names, duration, and reason for discontinuation (failure, intolerance, or contraindication)

FRAX score or other validated fracture risk assessment tool results

Clinical indication narrative explaining why the patient qualifies as high fracture risk

Many payers limit cumulative PTH analog therapy (teriparatide plus abaloparatide combined) to 24 months of lifetime use. If the patient has prior teriparatide exposure, document the cumulative duration to clarify remaining eligibility.

Specialty Pharmacy Routing: Best Practices

Send Tymlos prescriptions directly to a specialty pharmacy — not to a standard retail location. Major networks that dispense Tymlos include Accredo, CVS Specialty, Walgreens Specialty, Optum Specialty, and Biologics by McKesson. Each insurer has a preferred specialty pharmacy network; coordinate with your benefits coordinator or call the insurer's pharmacy line.

Establish a hub service relationship with Radius Health / Ipsen. Hub services can assist with PA submission, insurance verification, specialty pharmacy routing, and savings card enrollment — reducing the administrative burden on your office staff significantly.

Savings Programs Available for Your Patients

Be prepared to discuss cost and point patients to assistance programs:

Tymlos Savings Card: For commercially insured patients. Eligible patients may pay as little as $0/month. Phone: 1-855-243-6222; Web: tymloshcp.com/access-and-savings

Radius Assist (Together with Tymlos): For uninsured/underinsured patients meeting income criteria. Can provide up to 24 months of Tymlos at no cost. Phone: 1-866-896-5674

GoodRx for cash-pay patients: Reduces cash price to approximately $2,577–$2,852/month, compared to the $4,000+ list price

When to Consider Alternatives

If Tymlos remains inaccessible after PA submission and appeal, consider clinically appropriate alternatives:

Generic teriparatide (Teva, Alvogen): Similar PTH1R mechanism; FDA-approved generic versions available at significantly lower cost. Higher hypercalcemia rate than Tymlos.

Romosozumab (Evenity): Anti-sclerostin monoclonal antibody with dual anabolic/antiresorptive mechanism; 12 months monthly in-office injections. Contraindicated in patients with recent MI or stroke.

Denosumab (Prolia): Anti-RANKL q6 months; antiresorptive only. Important: do not discontinue without bisphosphonate transition.

Bisphosphonates: First-line for most patients; generic alendronate ~$10-$30/month. Appropriate as sequential therapy after anabolic agents or as sole therapy in moderate-risk patients.

Refer Patients to medfinder When Access Is Difficult

When patients are struggling to locate a pharmacy that carries Tymlos, medfinder for providers is a resource you can recommend. medfinder calls pharmacies near the patient to find which ones can fill the prescription — relieving the burden of pharmacy hunting from both patient and office staff.

See also our full provider guide: How to Help Your Patients Find Tymlos in Stock.